Century Therapeutics Stock Investor Sentiment

IPSC Stock  USD 1.30  0.09  7.44%   
About 58% of all Century Therapeutics' shareholders are looking to take a long position. The analysis of the overall investor sentiment regarding Century Therapeutics suggests that some traders are interested. The current market sentiment, together with Century Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use Century Therapeutics stock news signals to limit their universe of possible portfolio assets.
  

Century Therapeutics Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Century Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
over six months ago at news.google.com         
Century Therapeutics, Inc. Sees Large Decline in Short Interest - MarketBeat
Google News at Macroaxis
over six months ago at news.google.com         
HC Wainwright Trims Century Therapeutics Target Price to 11.00 - Defense World
Google News at Macroaxis
over six months ago at news.google.com         
Century Therapeutics expects cash to support operations into 2026 - TipRanks.com - TipRanks
Google News at Macroaxis
over six months ago at finance.yahoo.com         
Century Therapeutics Presents Preclinical Data Highlighting Advances in iPSC Platform Technology and...
Yahoo News
over six months ago at gurufocus.com         
Century Therapeutics Inc Q1 2024 Earnings Aligns with EPS Projections Amid Strategic ...
Gurufocus Stories at Macroaxis
over six months ago at finance.yahoo.com         
Century Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
Yahoo News
over six months ago at seekingalpha.com         
Century Therapeutics GAAP EPS of -0.45
seekingalpha News
over six months ago at investorplace.com         
IPSC Stock Earnings Century Therapeutics Beats EPS, Misses Revenue for Q1 2024
sbwire news
over six months ago at finance.yahoo.com         
Disposition of 913 shares by Adrienne Farid of Century Therapeutics at 3.106 subject to Rule 16b-3
Yahoo News
over six months ago at www.macroaxis.com         
Disposition of 5000 shares by Gregory Russotti of Century Therapeutics at 3.1238 subject to Rule 16b...
Macroaxis News
over six months ago at www.macroaxis.com         
Disposition of 913 shares by Adrienne Farid of Century Therapeutics at 3.106 subject to Rule 16b-3
Macroaxis News
over six months ago at www.macroaxis.com         
Acquisition by Adrienne Farid of 30684 shares of Century Therapeutics at 1.03 subject to Rule 16b-3
Macroaxis News
over six months ago at finance.yahoo.com         
Induced Pluripotent Stem Cell Market Size Projected to Surge 5.2 Billion Growth by 2033, Exhibit a C...
Yahoo News
over six months ago at investing.com         
Century Therapeutics executive sells shares worth over 15k
Investing News at Macroaxis
over six months ago at finance.yahoo.com         
Century Therapeutics to Present at Chardans 8th Annual Genetic Medicines and Cell Therapy Manufactur...
Yahoo News
Far too much social signal, news, headlines, and media speculation about Century Therapeutics that are available to investors today. That information is available publicly through Century media outlets and privately through word of mouth or via Century internal channels. However, regardless of the origin, that massive amount of Century data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Century Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Century Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Century Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Century Therapeutics alpha.

Century Therapeutics Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Acquisition by Quimi Daphne of 5000 shares of Century Therapeutics at 1.5314 subject to Rule 16b-3
09/12/2024
2
Century Therapeutics add two new members to its C-suite
09/26/2024
3
Insider Trading
10/01/2024
4
Disposition of 7452 shares by Luis Borges of Century Therapeutics at 1.03 subject to Rule 16b-3
10/08/2024
5
Disposition of 16611 shares by Carr Douglas of Century Therapeutics at 1.26 subject to Rule 16b-3
11/01/2024
6
Century Therapeutics Announces Upcoming Poster Presentations at the 2024 American Society of Hematology Annual Meeting
11/05/2024
7
Chardan Capital Has Lowered Expectations for Century Therapeutics Stock Price - MarketBeat
11/07/2024
8
FMR LLCs Strategic Reduction in Century Therapeutics Inc Holdin - GuruFocus.com
11/12/2024
9
Acquisition by Pfeiffenberger Brent of 573691 shares of Century Therapeutics at 1.61 subject to Rule 16b-3
11/25/2024

Complementary Tools for Century Stock analysis

When running Century Therapeutics' price analysis, check to measure Century Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Century Therapeutics is operating at the current time. Most of Century Therapeutics' value examination focuses on studying past and present price action to predict the probability of Century Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Century Therapeutics' price. Additionally, you may evaluate how the addition of Century Therapeutics to your portfolios can decrease your overall portfolio volatility.
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.